Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
ABEO
Abeona Therapeutics
$5.50
Chart
4.76
6.02
5.61
4.06
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
ABEO
Abeona Therapeutics
$5.50
Chart
4.76
6.02
5.61
4.06
ABEO Latest Headlines
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million. ) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the United States Food and Drug Administration (FDA) approval of ZEVASKYN™. (prademagene zamikeracel) on April 28 2025.Abeona Therapeutics Inc. ...
Today
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease. ) stock traded higher on Wednesday.The Food and Drug Administration (FDA) on Tuesday approved Abeona’.s Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets also known as pz-cel as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic .Zevaskyn is the only FDA-approved product to treat RDEB wounds.Zevaskyn consists of a patient&#
Wed Apr 30, 2025
Abeona Stock Surges to 52-Week High: Whats Behind The Move?. ) shares are trading higher on Wednesday on possible continued strength after the Food and Drug Administration (FDA) announced approval for The stock hit a new 52-week high of $7.32 today ...
Wed Apr 30, 2025
ABEO: Zevaskyn™ Approved by FDA. Raising Valuation to $11. By Business UpdateZevaskyn™ Approved by FDAOn April 29 2025 Abeona Therapeutics Inc. (NASDAQ:ABEO) announced that the United States Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic epidermolysis osa (RDEB). The company indicated that the commercial launch will commence in the third quarter of 2025. Zevaskyn will have a wholesale
Wed Apr 30, 2025
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy. The United States Food and Drug Administration (FDA) on Tuesday approved ) Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets also known as pz-cel as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic .RDEB isa severe genetically inherited skin disorder characterized by blistering and skin fragility often presenting at birth.Zevaskyn is t
Tue Apr 29, 2025
Abeona spikes on FDA nod for gene therapy.
Tue Apr 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABEO Stock trends
ABEO Stock performance
ABEO Stock analysis
ABEO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Don't Be a Sheep, Be a StocksRunner
StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score
Sign up for free and
continue analysing ABEO
Already a Member? Click here to Login
Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.
Don't Be a Sheep, Be a StocksRunner
StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score
Sign up for free and
continue analysing ABEO
Already a Member? Click here to Login
Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.
Login to display Abeona Therapeutics (ABEO) recommendation from the last 90 days from financial news and social media.
Hover over the category for more information
